首页> 外国专利> Drug composition for treating chronic liver disease and its application

Drug composition for treating chronic liver disease and its application

机译:一种治疗慢性肝病的药物组合物及其应用

摘要

A drug composition for treating chronic liver diseases, consists of: Astragalus Astragalosides and Glycyrrhiza Acid by weight ratio of 3˜6:1. By testing and validating with classic animal model, the results confirmed that the drug composition of the present invention can significantly reduce the collagen content of rat liver, and reduce liver fibrosis and liver injury, wherein the effect is better than the effect of each component alone. The drug composition of the two components or ingredients can improve the anti-hepatic fibrosis, effectively prevent liver fibrosis and promote the development of liver fibrosis reversal, and thus can be used for the treatment and prevention of various chronic hepatitis, liver fibrosis, cirrhosis and other illnesses.
机译:一种治疗慢性肝病的药物组合物,其组成为:黄芪黄芪总苷和甘草酸,重量比为3〜6:1。通过经典动物模型的测试和验证,结果证实本发明的药物组合物可以显着降低大鼠肝脏的胶原蛋白含量,减少肝纤维化和肝损伤,其效果优于单独使用每种成分的效果。 。两种成分或成分的药物组成可改善抗肝纤维化,有效预防肝纤维化,促进肝纤维化逆转的发展,因此可用于治疗和预防各种慢性肝炎,肝纤维化,肝硬化和其他疾病。

著录项

  • 公开/公告号US2012053135A1

    专利类型

  • 公开/公告日2012-03-01

    原文格式PDF

  • 申请/专利权人 PING LIU;

    申请/专利号US201113219402

  • 发明设计人 PING LIU;

    申请日2011-08-26

  • 分类号A61K31/704;A61P1/16;

  • 国家 US

  • 入库时间 2022-08-21 17:30:17

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号